TRIF Antibody
Code | Size | Price |
---|
PSI-3173-0.02mg | 0.02mg | £150.00 |
Quantity:
PSI-3173-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Images
Documents
Further Information
Additional Names:
TRIF Antibody: TRIF, IIAE6, MyD88-3, PRVTIRB, TICAM-1, TRIF, TIR domain-containing adapter molecule 1, Proline-rich, vinculin and TIR domain-containing protein B
Application Note:
TRIF antibody can be used for detection of TRIF by Western blot at 1 to 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 10 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
TRIF Antibody: TRIF is a member of the Toll/interleukin-1 receptor (TIR) family, a group of proteins that include the Toll-like receptors (TLRs). TLRs are signaling molecules that recognize different pathogen-associated molecular patterns (PAMPs) and serve as an important link between the innate and adaptive immune responses. TRIF, along with other molecules such as TIRP, TIRAP, and MyD88, serves as an adaptor protein to several of the TLR molecules. Following activation of TLR3 and TLR4, TRIF engages the kinase TBK1 and allows its subsequent activation of the interferon regulatory factor (IRF)-3. TRIF is also involved in the activation of TNF receptor associated factor (TRAF)-6, and ultimately the activation of NF-κB.
Background References:
- O'Neill LAJ, Fitzgerald FA, and Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends in Imm. 2003; 24:286-9.
- Vogel SN, Fitzgerald KA, and Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol. Interv. 2003;3:466-77.
- Takeda K, Kaisho T, and Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003;21:335-76.
- Janeway CA Jr and Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002;20:197-216.
Buffer:
TRIF Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
TRIF antibody was raised against a peptide corresponding to 14 amino acids near the C-terminus of human TRIF.
The immunogen is located within the last 50 amino acids of TRIF.
The immunogen is located within the last 50 amino acids of TRIF.
NCBI Gene ID #:
148022
NCBI Official Name:
toll-like receptor adaptor molecule 1
NCBI Official Symbol:
TICAM1
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 60 kDa
Observed: 55 kDa
Observed: 55 kDa
Protein Accession #:
NP_891549
Protein GI Number:
41281981
Purification:
TRIF Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
Swissprot #:
Q8IUC6
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
Product Name | Product Code | Supplier | TRIF Peptide | PSI-3173P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|